Trial
NCT05964413
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
InflaRx GmbH
Collaborators
—
Condition
Pyoderma Gangrenosum
Intervention
vilobelimab
Why stopped
Study stopped for futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-04